Dogwood Therapeutics grants CFO 82,500 stock options

Dogwood Therapeutics, Inc. reported that its Chief Financial Officer, Angela Walsh, received a grant of stock options covering 82,500 shares on March 5, 2026.

Rhea-AI Filing Summary

Dogwood Therapeutics, Inc. reported that its Chief Financial Officer, Angela Walsh, received a grant of stock options covering 82,500 shares on March 5, 2026. These options give her the right to buy company stock if and when she chooses to exercise them.

According to the filing, Walsh now holds 82,500 stock options following this award. The options vest over time, with one-third vesting on March 5, 2027 and the remaining amount vesting in equal 1/24th monthly installments thereafter, creating a multi‑year retention and incentive structure.

Insider Trade Summary

Grant/Award: 82,500 shares

Grant/Award 1 txn

Insider Walsh Angela

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	82,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 82,500 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests one-third on March 5, 2027 and 1/24th monthly thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Dogwood Therapeutics (DWTX) disclose for Angela Walsh?

Dogwood Therapeutics disclosed that CFO Angela Walsh received a stock option grant for 82,500 shares on March 5, 2026. The award increases her stock-based incentives and aligns part of her compensation with the company’s future share performance over a multi‑year vesting period.

How many stock options does the Dogwood Therapeutics (DWTX) CFO hold after this Form 4?

After this transaction, CFO Angela Walsh holds 82,500 stock options in Dogwood Therapeutics. The filing indicates this entire amount comes from the newly reported grant, giving her potential future ownership exposure tied to the company’s stock, subject to the award’s time-based vesting schedule.

What is the vesting schedule for Angela Walsh’s Dogwood Therapeutics (DWTX) stock options?

The stock options granted to CFO Angela Walsh vest one-third on March 5, 2027, with the remaining two-thirds vesting in 1/24th monthly installments thereafter. This gradual vesting structure encourages long-term alignment with Dogwood Therapeutics by spreading the benefit over several years of continued service.

Is the Dogwood Therapeutics (DWTX) CFO’s Form 4 transaction a purchase or an award?

The Form 4 transaction for Dogwood Therapeutics’ CFO is an award of stock options, not an open-market purchase. It is coded as a grant or other acquisition, meaning the company granted her 82,500 options as part of compensation rather than her buying shares in the market.

What does the Dogwood Therapeutics (DWTX) Form 4 reveal about executive compensation structure?

The Form 4 shows that Dogwood Therapeutics uses stock options as part of its executive compensation. CFO Angela Walsh received 82,500 options that vest over several years, tying a portion of her potential reward directly to the company’s share performance and her continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 04:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Walsh Angela

(Last) (First) (Middle)

C/O DOGWOOD THERAPEUTICS, INC.

44 MILTON AVENUE

(Street)

ALPHARETTA GA 30009

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Dogwood Therapeutics, Inc. [ DWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.86	03/05/2026		A		82,500		(1)	03/05/2036	Common Stock	82,500	$0	82,500	D

Explanation of Responses:

1. The stock option vests one-third on March 5, 2027 and 1/24th monthly thereafter.

	/s/ Greg Duncan, Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.